Table 7.
OR with 95% CI of developing MS for subjects with different combinations of DRB1*15:01, A*02:01, and IM history compared to subjects with no IM history and without the genetic risk factors, overall and stratified by anti-EBNA-1 status (relative access proportion due to interaction, RERI).
| Total | High anti-EBNA-1 antibody levels | Low anti-EBNA-1 antibody levels | |||||||
|---|---|---|---|---|---|---|---|---|---|
| DRB1*15:01 | A*02:01 | IM history | ca/coa | OR (95% CI)b | OR (95% CI)c | ca/coa | OR (95% CI)d | ca/coa | OR (95% CI)d |
| – | + | – | 779/1,931 | 1.0 (reference) | 1.0 (reference) | 515/916 | 1.0 (reference) | 264/1,015 | 1.0 (reference) |
| – | – | – | 1,123/1,584 | 1.8 (1.6–2.0) | 1.8 (1.6–2.0) | 808/749 | 1.9 (1.7–2.2) | 315/835 | 1.5 (1.2–1.8) |
| + | + | – | 1,210/816 | 3.7 (3.3–4.2) | 4.2 (3.7–4.8) | 957/469 | 4.1 (3.5–4.8) | 253/347 | 3.3 (2.7–4.2) |
| + | – | – | 1,395/598 | 5.9 (5.2–6.7) | 7.0 (6.1–8.0) | 1,160/350 | 7.1 (6.0–8.4) | 235/248 | 4.6 (3.6–5.9) |
| – | + | + | 106/192 | 1.4 (1.1–1.8) | 1.5 (1.1–1.9) | 77/96 | 1.5 (1.1–2.1) | 29/96 | 1.3 (0.8–2.1) |
| – | – | + | 227/170 | 3.3 (2.7–4.1) | 3.4 (2.7–4.2) | 167/92 | 3.2 (2.4–4.2) | 60/78 | 3.0 (2.1–4.4) |
| + | + | + | 178/74 | 6.0 (4.5–8.1) | 6.8 (5.1–9.1) | 143/47 | 6.1 (4.2–8.7) | 35/27 | 6.3 (3.7–10.9) |
| + | – | + | 298/66 | 11.4 (8.6–15.1) | 14.1 (10.6–18.9) | 254/47 | 11.9 (8.5–16.8) | 44/19 | 11.9 (6.7–21.2) |
| RERI 8.7 (4.7–12.6) | RERI 6.4 (2.5–10.3) | RERI 7.8 (1.0–14.6) | |||||||
Number of exposed cases and controls.
Adjusted for age, gender, residential area, study, and ancestry.
Adjusted for age, gender, residential area, study, ancestry, anti-EBNA1 status, smoking, adolescent body mass index, DRB1*03:01, DRB1*13:03, DRB1*08:01, B*44:02, B*38:01, B*55:01, DQA1*01:01, DQB1*03:01, and DQB1*03:02.
Adjusted for age, gender, residential area, study, ancestry, smoking, adolescent body mass index, DRB1*03:01, DRB1*13:03, DRB1*08:01, B*44:02, B*38:01, B*55:01, DQA1*01:01, DQB1*03:01, and DQB1*03:02.